Condition

Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials and research

• 47Clinical trials
• 5NIH research projects
• 1New in 30 days
• 23Countries

Newest Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials

All recruiting trials (47)

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• Modified FOLFIRINOX with Pentamidine in Advanced Pancreatic Cancer

  This study tests whether adding pentamidine to a modified FOLFIRINOX regimen helps people with advanced or metastatic pancreatic cancer.

  Recruiting Phase 1 University of Oklahoma · Oklahoma City, Oklahoma · NCT07829185

• Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502

  This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.

  Recruiting Phase 1 SK Life Science, Inc. · Glen Burnie, Maryland and 4 other locations · NCT07812805

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Reach and Engagement of Genetic Education, Risk Assessment, and Testing Feasibility (GENET) for PDAC risk

  This study tests whether online education plus a phone call from PanCAN helps Black, Latino/a, and Medicaid-enrolled people in Massachusetts learn about genetic and multi-cancer early detection testing and decide about getting tested.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT07787156

• Imaging study of 203Pb-RMX-VH-PIB in GBM and PDAC patients

  This early-stage study tests a new imaging drug to see how it travels in the body and how much radiation different organs receive in adults with GBM or PDAC.

  Recruiting Phase 1 Radiomedix, Inc. · Houston, Texas · NCT07733674

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

• [68Ga]BED003 PET imaging to see fibroblast activity in selected cancers

  This study tests a PET imaging agent, [68Ga]BED003, to see how well it detects tumors in colorectal, gastric, pancreatic, ovarian, and invasive lobular breast cancers.

  Recruiting at 5 sites Phase 2 Blue Earth Diagnostics · Bergamo, Lombardy and 5 other locations · NCT07702292

• Patient-Derived Organoids on a Chip to Predict Chemotherapy Response in PDAC

  Researchers are testing a patient-derived organoid-on-a-chip model to see if it can predict how individual pancreatic cancer patients will respond to chemotherapy.

  Recruiting Beijing Daxiang Biotech Co., Ltd · Shanghai, Shanghai Municipality · NCT07683845

• KRAS G12D-mutated pancreatic cancer: VS-7375 with or without cetuximab

  This study tests whether VS-7375, alone or with cetuximab, can help people with metastatic PDAC that carries the KRAS G12D mutation.

  Recruiting at 38 sites Phase 2 Verastem, Inc. · Los Angeles, California and 37 other locations · NCT07644559

• Dual-target CAR-NK cells targeting MSLN + MUC1 or CLDN18.2 + MUC1 in advanced PDAC

  Aimed at people with advanced pancreatic cancer, this trial tests two off-the-shelf CAR-NK cell products to see if they are safe and can slow or shrink tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07627711

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• NALIRIFOX plus adebrelimab and PULSAR as first-line treatment for advanced pancreatic cancer

  This study tests a combination of NALIRIFOX chemotherapy with adebrelimab and PULSAR as first-line therapy for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma to see if it is safe and shows initial signs of effectiveness.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07595172

• Personalized mRNA tumor vaccine plus standard therapy for high-risk recurrent solid tumors

  This early-phase study tests XH001, a personalized mRNA neoantigen vaccine, with standard adjuvant treatment in people with high-risk recurrent solid cancers after surgery to see if it’s safe and may help delay relapse.

  Recruiting at 2 sites Phase 1 Shenzhen Xinhe Biomedical · Beijing and 1 other locations · NCT07594964

• Panuri test in suspected pancreatic cancer patients

  This study tests the Panuri urine test to see if it helps detect pancreatic ductal adenocarcinoma in adults with symptoms suggesting pancreatic cancer.

  Recruiting at 10 sites Urteste S.A · Békéscsaba and 31 other locations · NCT07587866

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Structured lipid nutrition for people with pancreatic cancer

  Try a structured lipid medical food (Encala) to help people with pancreatic cancer who have trouble absorbing fat.

  Recruiting at 2 sites Children's Hospital of Philadelphia · Philadelphia, Pennsylvania and 1 other locations · NCT07554560

• NEO-Match nanomechanical testing of pancreatic tumor samples

  This will test whether the NEO-Match® nanomechanical test on biopsy tissue can help predict response to pre-surgery treatment and detect cancer in people with suspected pancreatic tumors.

  Recruiting Artidis Ag · Tampa, Florida · NCT07542041

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• Dual-target CAR-NK therapy targeting mesothelin and MUC1 for advanced pancreatic cancer

  This study will test whether two off-the-shelf CAR-NK cell therapies that target mesothelin or MUC1 are safe and can shrink tumors in people with advanced pancreatic cancer whose tumors express those proteins.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07480928

• Nuzefatide pevedotin (BT5528) for metastatic pancreatic ductal adenocarcinoma

  This trial tests nuzefatide pevedotin (BT5528), a drug designed to find the EphA2 protein on cancer cells, in adults whose metastatic pancreatic cancer has worsened after one prior systemic treatment.

  Recruiting at 8 sites Phase 2 BicycleTx Limited · Phoenix, Arizona and 7 other locations · NCT07450859

• BPI-572270 in RAS-mutant advanced solid tumors (including NSCLC, CRC, PDAC)

  This study tests whether BPI-572270 is safe and tolerable in adults with RAS-mutant advanced solid tumors and looks for signs of clinical activity.

  Recruiting Phase 1/2 Betta Pharmaceuticals Co., Ltd. · Blacktown, New South Wales and 6 other locations · NCT07435038

• Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors

  This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410494

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• RNK08954 treatment for metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutation

  This study tests whether RNK08954 is safe and helps people with metastatic pancreatic ductal adenocarcinoma who have a KRAS G12D mutation.

  Recruiting at 2 sites Phase 2 Ranok Therapuetics Co. Ltd. · Nanjing and 1 other locations · NCT07303465

• Pumitamig combined with chemotherapy for people with untreated metastatic pancreatic cancer

  This trial will test whether adding pumitamig (BNT327) to standard chemotherapy helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma who have not yet had systemic treatment.

  Recruiting at 14 sites Phase 2 BioNTech SE · Bedford Park and 23 other locations · NCT07255404

• Using Hand Grip Tests to Understand Muscle Strength in Pancreatic Cancer

  This study tests whether hand grip strength can be measured during regular clinic visits and whether grip strength relates to body composition, wellbeing, and tumor response in adults with pancreatic ductal adenocarcinoma.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT07255001

• MR001 plus chemotherapy for advanced or metastatic pancreatic ductal adenocarcinoma after first-line therapy

  This trial will test whether adding MR001 to standard chemotherapy helps people with locally advanced or metastatic pancreatic ductal adenocarcinoma whose disease progressed after first-line therapy.

  Recruiting at 4 sites Phase 1/2 Shenzhen Majory Biotechnology Co., Ltd. · Beijing, Beijing Municipality and 17 other locations · NCT07235202

• STRO-004 treatment in adults with recurrent or metastatic solid tumors

  This study will test whether STRO-004, alone and with pembrolizumab, is safe and can shrink tumors in adults with several types of metastatic cancers that often express Tissue Factor.

  Recruiting at 9 sites Phase 1 Sutro Biopharma, Inc. · San Diego, California and 8 other locations · NCT07227168

• Noninvasive blood miRNA test to screen for multiple gastrointestinal cancers.

  This project will test whether a blood-based microRNA panel can detect several types of gastrointestinal cancer in adults using stored blood samples.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07224750

• BMS-986523 alone and with other cancer medicines for advanced KRAS-altered solid tumors

  This treatment tests whether BMS-986523, alone or combined with chemotherapy or immunotherapy, helps people with advanced KRAS-altered lung, colorectal, or pancreatic cancers.

  Recruiting at 6 sites Phase 1/2 Bristol-Myers Squibb · Baltimore, Maryland and 7 other locations · NCT07223047

• 18F‑FAPI PET/CT to detect metastatic pancreatic ductal adenocarcinoma

  This study will try a single [18F]FAPI‑74 PET/CT scan to see if it finds metastatic disease in adults with confirmed pancreatic ductal adenocarcinoma.

  Recruiting at 17 sites Phase 3 Sofie · Cerritos, California and 18 other locations · NCT07217717

• YntraDose™ given before chemotherapy for locally advanced, unresectable pancreatic cancer

  This will test whether a one-time, image-guided injection of YntraDose™ (Y-90 radioactive microspheres) into the pancreatic tumor, combined with standard chemotherapy, is safe and can help control locally advanced unresectable pancreatic cancer.

  Recruiting at 2 sites BetaGlue Therapeutics SpA · Roma and 1 other locations · NCT07155850

• Intraperitoneal paclitaxel plus NALIRIFOX for pancreatic cancer that has spread to the peritoneum

  This trial tests whether giving paclitaxel into the abdomen together with intravenous NALIRIFOX is safe and helps adults whose pancreatic cancer has spread to the peritoneum.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT07030283

• Evaluating MT-4561 in Patients with Advanced Solid Tumors

  This study is testing a new drug called MT-4561 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 6 sites Phase 1/2 Tanabe Pharma America, Inc. · Los Angeles, California and 5 other locations · NCT06943521

• JYP0015 for adults with advanced RAS‑mutant solid tumors

  This trial tests whether the oral drug JYP0015 is safe and can shrink tumors in adults whose advanced solid cancers have specific RAS mutations.

  Recruiting Phase 2 Guangzhou JOYO Pharma Co., Ltd · Beijing, Beijing Municipality · NCT06895031

• PET-FAPI imaging to find pancreatic cancer earlier

  This will try a PET scan using a FAPI tracer to find early or returning pancreatic cancer in adults with recently diagnosed non‑metastatic PDAC who are enrolled in the HoMING cohort.

  Recruiting Phase 2 Institut Curie · Saint-Cloud · NCT06659705

• Combining Fostamatinib with Gemcitabine and Nab-paclitaxel for Pancreatic Cancer Treatment

  This study is testing if adding a new drug called Fostamatinib to standard chemotherapy can help improve treatment outcomes for patients with operable pancreatic cancer.

  Recruiting Phase 1 University of California, San Diego · La Jolla, California · NCT06639724

• ProAgio treatment for advanced pancreatic cancer

  This study is testing a new treatment called ProAgio combined with standard chemotherapy to see if it helps people with advanced pancreatic cancer feel better and live longer.

  Recruiting Phase 1 ProDa BioTech, LLC · Birmingham, Alabama · NCT06182072

• Evaluating RMC-9805 for KRAS G12D-Mutant Solid Tumors

  This study is testing a new drug called RMC-9805 to see if it can safely help adults with solid tumors that have a specific KRAS G12D mutation.

  Recruiting at 17 sites Phase 1 Revolution Medicines, Inc. · Sacramento, California and 16 other locations · NCT06040541

• Testing KO-2806 for advanced solid tumors

  This study is testing a new treatment called KO-2806 for adults with advanced solid tumors that have certain genetic changes to see if it can help them feel better.

  Recruiting at 38 sites Phase 1 Kura Oncology, Inc. · Phoenix, Arizona and 37 other locations · NCT06026410

• Assessing safety and efficacy of new treatments for advanced solid tumors

  This study is testing two new treatments for patients with advanced solid tumors to see if they are safe and effective.

  Recruiting at 10 sites Phase 1/2 Lumara Bio Oncologics GmbH · Melbourne and 9 other locations · NCT05706129

• Evaluating RMC-6236 for advanced solid tumors with specific RAS mutations

  This study is testing a new drug called RMC-6236 to see if it can help adults with advanced solid tumors that have certain RAS mutations.

  Recruiting at 21 sites Phase 1/2 Revolution Medicines, Inc. · Orange, California and 20 other locations · NCT05379985

• Using ultrasound-guided radiofrequency ablation with chemotherapy for pancreatic cancer treatment

  This study is testing if combining a special ultrasound treatment with chemotherapy can help shrink pancreatic cancer tumors before surgery to make the surgery easier and more successful for patients.

  Recruiting Phase 2 The University of Texas Health Science Center, Houston · Houston, Texas · NCT04990609

• Innovative therapies for liver metastases in cancer patients

  This study is testing new ways to understand and treat liver tumors in patients with advanced colorectal and pancreatic cancer to see if it can lead to better therapies.

  Recruiting IRCCS San Raffaele · Milan, Milan · NCT04622423

• Exploring RPSA as a biomarker for pancreatic cancer prognosis

  This study is testing if a protein found in blood can help predict how pancreatic cancer will progress in patients who have had surgery or chemotherapy.

  Recruiting CHU de Reims · Reims · NCT04575363

• Evaluating tumor types in pancreatic cancer patients receiving FOLFIRINOX treatment

  This study is testing how different types of pancreatic cancer respond to the chemotherapy FOLFIRINOX before surgery to see if it helps make the tumors easier to remove.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT03977233

NIH-funded research (5)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Investigating how a specific protein affects pancreatic cancer growth and spread

  This study is looking at a protein called RCC1 to see how it affects pancreatic cancer cells, with the hope that understanding its role could help develop new treatments for patients facing this tough disease.

  NIH research Wayne State University · Detroit, United States · NIH-11228868

• AI to find early signs of pancreatic cancer on routine CT scans

  Uses artificial intelligence to look at routine abdominal CT scans and medical information to find people likely to develop pancreatic cancer within three years.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11172502

• Using AI to predict pancreatic cancer risk in African Americans from CT scans

  This study is using advanced computer technology to look at CT scans and help find out which African Americans might be at higher risk for pancreatic cancer in the next ten years, so that doctors can catch it early and improve treatment options.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11014899

• Investigating how a specific protein affects pancreatic cancer growth

  This study is looking at how a protein called RCC1 affects the growth of pancreatic cancer, with the hope that understanding its role could help develop new treatments for patients facing this tough diagnosis.

  NIH research Wayne State University · Detroit, United States · NIH-10987453

• Using AI to predict pancreatic cancer risk from CT scans

  This study is looking to use artificial intelligence to help spot people who might be at high risk for pancreatic cancer by analyzing CT scans and other information, so that doctors can catch the disease early and improve chances of survival.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-10911178

Related topics

Quick answers

How many Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials are recruiting right now?

47, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 23 countries. The most sites are in United States (27 trials), China (11 trials), Italy (7 trials), Australia (6 trials), United Kingdom (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 11, Phase 1/2: 11, Phase 2: 9, Phase 3: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →